Table 1.
Active and Passive targeted nanoformulations of Doxorubicin, Paclitaxel, and cisplatin.
| Name | Drug Payload/ Nanoformulation |
Investigated Clinical Application(s) |
Status |
|---|---|---|---|
| Doxil® | Doxorubicin/Liposomal doxorubicin (PEGylated) | Ovarian cancer (secondary to platinum-based therapies), HIV-associated Kaposi’s sarcoma (secondary to chemotherapy), Multiple myeloma (secondary. Various cancers including solid malignancies, ovarian, breast, leukemia, lymphomas, prostate, metastatic, or liver | FDA Approved (1995) |
| 2B3-101 | Doxorubicin/Liposomal doxorubicin (PEGylated) | Advanced solid tumors, brain metastases, lung and breast cancers, melanoma, malignant glioma | Phase I/II Completed |
| ANTI-EGFR-IL-DOX | Doxorubicin/Doxorubicin-loaded anti-EGFR immunoliposomes | Advanced triple negative EGFR positive breast cancer, High grade gliomas | Phase II: Recruiting Phase I: Recruiting |
| MM-302 | Doxorubicin/HER2-targeted liposomal doxorubicin (PEGylated) | Breast cancer | Phase II/III: Terminated Phase I: Unknown Phase I: Withdrawn |
| MCC-465 | Doxorubicin/F(ab″)2 fragment of human mAb GAH | Metastatic stomach cancer | Phase I/II terminated |
| Abraxane | Paclitaxel/Albumin-particle bound paclitaxel | Pancreatic cancer, Metastatic breast cancer, NSCLC, Triple negative breast cancer | FDA Approved (2005, 2021, 2013, 2019) |
| LIPUSU® | Paclitaxel/Paclitaxel liposome | Advanced solid tumors, or gastric, breast cancer | Phase IV: Unknown Phase IV: Unknown Phase II: Unknown Phase IV: Not yet recruiting |
| Cynviloq | Paclitaxel/Paclitaxel polymeric micelle nanoparticle | Breast cancer | Not provided: NCT02064829 |
| Genexol-PM | Paclitaxel/Paclitaxel polymeric micelle nanoparticle | Head and neck or breast cancer | Phase II: Unknown Phase II: Completed Phase IV: Unknown Phase II: Recruiting Phase II: Recruiting |
| NK105 | Paclitaxel/Paclitaxel micelle | Breast cancer | Phase III: Completed |
| Paclical | Paclitaxel micelle | Ovarian Cancer | Phase III: Completed |
| EndoTAG-1 | Paclitaxel Liposome | Pancreatic Cancer; Breast cancers | Phase III: in progress; Phase III: in progress |
| LiPlaCis | Cisplatin/Liposomal formulated cisplatin with specific degradation-controlled drug release via phospholipase A2 (PLA2) | Advanced or refractory tumors | Phase I: Recruiting |
| Nanoplatin | Cisplatin/Polyamino acid, PEG, and cisplatin derivative micellar nanoparticle | Advanced solid tumors, lung, biliary, bladder, or pancreatic cancers | Phase I/II: Active, not recruiting Phase III: Unknown Phase II: Not yet recruiting Phase I: Completed Phase I: Unknown |
| This table is assembled based on https://clinicaltrials.gov/ and other sources mentioned in this review. | |||